Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia

Cancer Cell

Volumn 24, Issue 6, 2013, Pages 766-776

  Piovan, Erich ^a,b,c   Yu, Jiyang ^a   Tosello, Valeria ^a,b   Herranz, Daniel ^a   Ambesi Impiombato, Alberto ^a   DaSilva, AnaCarolina ^a   Sanchez Martin, Marta ^a   Perez Garcia, Arianne ^a   Rigo, Isaura ^a   Castillo, Mireia ^d   Indraccolo, Stefano ^b   Cross, JustinR ^e   deStanchina, Elisa ^e   Paietta, Elisabeth ^f,g   Racevskis, Janis ^f,g   Rowe, JacobM ^h   Tallman, MartinS ^e   Basso, Giuseppe ^c   Meijerink, JulesP ⁱ   Cordon Cardo, Carlos ^d   Califano, Andrea ^a   Ferrando, AdolfoA ^a,d,j   more..

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h SHAARE ZEDEK MEDICAL CENTER   (Israel)

ⁱ SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^j NewYork Presbyterian Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT;

EID: 84891913160     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.10.022     Document Type: Article

References (33)

1. Armstrong F., Brunet de la Grange P., Gerby B., Rouyez M.C., Calvo J., Fontenay M., Boissel N., Dombret H., Baruchel A., Landman-Parker J., et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009, 113:1730-1740.
2. Ayroldi E., Zollo O., Bastianelli A., Marchetti C., Agostini M., Di Virgilio R., Riccardi C. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J.Clin. Invest. 2007, 117:1605-1615.
3. Bandapalli O.R., Zimmermann M., Kox C., Stanulla M., Schrappe M., Ludwig W.D., Koehler R., Muckenthaler M.U., Kulozik A.E. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica 2013, 98:928-936.
4. Beesley A.H., Firth M.J., Ford J., Weller R.E., Freitas J.R., Perera K.U., Kees U.R. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br. J. Cancer 2009, 100:1926-1936.
5. Bhadri V.A., Trahair T.N., Lock R.B. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J.Paediatr. Child Health 2012, 48:634-640.
6. Bornhauser B.C., Bonapace L., Lindholm D., Martinez R., Cario G., Schrappe M., Niggli F.K., Schäfer B.W., Bourquin J.P. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 2007, 110:2084-2091.
7. Chiang M.Y., Xu L., Shestova O., Histen G., L'heureux S., Romany C., Childs M.E., Gimotty P.A., Aster J.C., Pear W.S. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J.Clin. Invest. 2008, 118:3181-3194.
8. D'Adamio F., Zollo O., Moraca R., Ayroldi E., Bruscoli S., Bartoli A., Cannarile L., Migliorati G., Riccardi C. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997, 7:803-812.
9. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., Tsang B.K., Cheng J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J.Biol. Chem. 2004, 279:5405-5412.
10. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
11. del Peso L., González-García M., Page C., Herrera R., Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689.
12. Dördelmann M., Reiter A., Borkhardt A., Ludwig W.D., Götz N., Viehmann S., Gadner H., Riehm H., Schrappe M. Prednisone response isthe strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999, 94:1209-1217.
13. Geng C.D., Schwartz J.R., Vedeckis W.V. A conserved molecular mechanism is responsible for the auto-up-regulation of glucocorticoid receptor gene promoters. Mol. Endocrinol. 2008, 22:2624-2642.
14. Guo K., McMinn J.E., Ludwig T., Yu Y.H., Yang G., Chen L., Loh D., Li C., Chua S., Zhang Y. Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. Endocrinology 2007, 148:3987-3997.
15. Heitzer M.D., Wolf I.M., Sanchez E.R., Witchel S.F., DeFranco D.B. Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 2007, 8:321-330.
16. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., Ueno Y., Hatch H., Majumder P.K., Pan B.S., Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs invitro and invivo. Mol. Cancer Ther. 2010, 9:1956-1967.
17. Hongo T., Yajima S., Sakurai M., Horikoshi Y., Hanada R. Invitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997, 89:2959-2965.
18. Inaba H., Pui C.H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010, 11:1096-1106.
19. Kharas M.G., Okabe R., Ganis J.J., Gozo M., Khandan T., Paktinat M., Gilliland D.G., Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010, 115:1406-1415.
20. Klumper E., Pieters R., Veerman A.J., Huismans D.R., Loonen A.H., Hählen K., Kaspers G.J., van Wering E.R., Hartmann R., Henze G. Invitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995, 86:3861-3868.
21. Mok C.L., Gil-Gómez G., Williams O., Coles M., Taga S., Tolaini M., Norton T., Kioussis D., Brady H.J. Bad can act as a key regulator of Tcellapoptosis and Tcell development. J.Exp. Med. 1999, 189:575-586.
22. Morishita N., Tsukahara H., Chayama K., Ishida T., Washio K., Miyamura T., Yamashita N., Oda M., Morishima T. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr. Blood Cancer 2012, 59:83-89.
23. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85.
24. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., Caparros E., Buteau J., Brown K., Perkins S.L., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 2007, 13:1203-1210.
25. Pui C.H., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011, 29:551-565.
26. Pui C.H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012, 120:1165-1174.
27. Riccardi C., Cifone M.G., Migliorati G. Glucocorticoid hormone-induced modulation of gene expression and regulation of T-cell death: role of GITR and GILZ, two dexamethasone-induced genes. Cell Death Differ. 1999, 6:1182-1189.
28. Schlossmacher G., Stevens A., White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J.Endocrinol. 2011, 211:17-25.
29. Schmidt S., Rainer J., Riml S., Ploner C., Jesacher S., Achmüller C., Presul E., Skvortsov S., Crazzolara R., Fiegl M., et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006, 107:2061-2069.
30. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., et al. Ptendose dictates cancer progression in the prostate. PLoS Biol. 2003, 1:E59.
31. Wang Z., Malone M.H., He H., McColl K.S., Distelhorst C.W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J.Biol. Chem. 2003, 278:23861-23867.
32. Wei G., Twomey D., Lamb J., Schlis K., Agarwal J., Stam R.W., Opferman J.T., Sallan S.E., den Boer M.L., Pieters R., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10:331-342.
33. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744.